"paper"

Our authors of the month for September conclude that people with Parkinson's Disease and parkinsonism showed a higher risk of SARS-CoV-2 infection throughout the first 15 months of the pandemic.

Our research paper of the month presents the results of the ‘SWIFT direct’ trial, a randomised, open-label, blinded-outcome trial, aiming to investigate whether thrombectomy alone would be non-inferior to thrombectomy plus intravenous alteplase in patients with acute ischaemic stroke due to anterior circulation large vessel occlusion.

Our research paper of the month is a meta-analysis investigating the influence of intraventricular fibrinolysis on functional outcomes in patients with intracerebral haemorrhage.

Our authors of the month conducted this study in which COVID-19 patients with neurological symptoms and cognitive impairments, underwent DMI in the subacute stage of the disease.

In this population-based study, the authors aimed to investigate whether increased life expectancy determined by the adherence to a healthy lifestyle has an impact on the overall years lived with AD across the lifespan.

To evaluate the association of COVID-19 infection with olfactory bulb, our authors of the month conducted this multicenter postmortem cohort study, using ultrastructural and histopathological analysis.

The EAN NeuroCOVID-19 Task Force has published a position paper on COVID-19 vaccination hesitancy among people with chronic neurological disorders in the European Journal of Neurology.

Our authors of the month evaluated an experimental treatment for human prion disease, based on a fully humanised monoclonal antibody (PRN100) addressed against the cellular prion protein (PrP).

Our authors of the month conducted this retrospective case-control study in order to investigate the association of AD with the risk of COVID-19 infection (adjusted for comorbidities and sociodemographic factors).

Our paper of the month describes a study led by Stanford University researchers, which now provides a mechanistic basis for how EBV infection can trigger the patient’s immune cells to attack self-tissue within the CNS.

Our authors of the month conducted a longitudinal, multi-modal brain imaging study using the UK biobank, whereby participants had already been scanned before getting infected with SARS-CoV-2, offering a unique resource to elucidate these questions.

Our authors of the month conducted a systematic retrospective analysis of 150 lumbar punctures in 127 patients with PCR-proven COVID-19 and neurological symptoms seen at 17 European university centres.

Our research paper of the month for March is a cohort study exploring the risk of developing multiple sclerosis (MS) after infection with Epstein-Barr virus (EBV).

Our authors of the month conducted a systematic review and meta-analysis in order to summarise the frequency of neurologic manifestations in patients with COVID-19 and to investigate the association of these manifestations with disease severity and mortality.

For February we have selected Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomized, placebo-controlled trial.